Sofia Wen, Founder and CEODespite the hope they carry, many of these discoveries never make it to the patients who need them most. They remain confined to research papers, circulating in academic circles, but falling short of delivering practical value in the clinic. Physicians continue to face unanswered questions, laboratories accumulate unused findings, and patients wait for tools that could transform their care.
Dunwill Medical was founded to break this cycle.
The company’s mission is to ensure that the enormous potential of biomarker research is translated into real-world diagnostic products that physicians and patients can trust. By positioning itself at the intersection of clinical practice, cutting-edge science, and industrialization expertise, Dunwill ensures that ideas born in the laboratory are transformed into solutions that directly improve outcomes at the bedside.
“Our best R&D capability is not to create a fancy idea,” says Sofia Wen, founder and CEO. “It is to take a doctor’s idea and bring it to life as a dependable IVD product.”
Innovation Rooted in Clinical Practice
The cornerstone of Dunwill’s approach is what the company describes as its “Stronger together” model. Its innovation process begins in the hospital, at the point of patient care. The first step in every project is not a new piece of technology or an abstract research idea, but the real challenges that physicians and surgeons encounter daily.
If a surgeon struggles with unclear diagnostic results or if a physician faces limitations in current testing methods, that pain point becomes the starting point for Dunwill’s work. By partnering with clinicians, listening to their needs, and involving them from the earliest stages, the company ensures that the developed solutions are immediately relevant, practical, and actionable.
This model is compelling in China, where translational medical research has advanced internationally. Chinese hospitals and research institutes are increasingly recognized as leaders in basic and applied medical science. Dunwill leverages this ecosystem by collaborating with some of the nation’s most respected hospitals and clinical experts. Through these collaborations, the company can identify unmet clinical needs, connect them with emerging biomarker discoveries, and then apply its proven industrialization capabilities to transform those discoveries into finished diagnostic products.
By combining the insights of top-tier physicians with world-class R&D systems, Dunwill ensures continuous and meaningful innovation. The company does not chase trends or pursue technology for its own sake. Instead, every project is anchored to improve patient care in the real world.
Overcoming Barriers in Biomarker Translation
Dunwill Medical transforms complex biomarker discoveries into reliable diagnostics by mastering validation, scalability, and regulatory hurdles. This ensures that breakthroughs deliver real, actionable benefits in clinical practice.
The company provides clinicians and partners with access to advanced discovery platforms, bioinformatics support, and AI-driven data analysis tools that many hospitals lack internally. These resources allow clinical experts to focus on their strengths while Dunwill takes responsibility for ensuring that every biomarker is thoroughly validated, industrially scalable, and compliant with regulatory standards.
Throughout the process, clinicians remain active participants. They supply real-world samples, evaluate assay performance, and provide feedback on clinical utility. This partnership guarantees that the end product is scientifically sound and practical.
Perhaps the most compelling demonstration of Dunwill’s model in action is the development of the miRNA7 kit. This story began in 2011, when the liver surgery team at Shanghai Zhongshan Hospital identified seven microRNA biomarkers that showed strong potential for improving the detection of hepatocellular carcinoma (HCC), one of the most common and deadly forms of liver cancer. Their findings were published in the Journal of Clinical Oncology, drawing significant attention in the research community.
However, like many promising discoveries, these biomarkers risked remaining an academic achievement rather than a clinical tool. That is where Dunwill stepped in. Working closely with the hospital’s clinicians, the company transformed these biomarkers into a quantitative IVD assay. In 2017, the resulting miRNA7 kit became the world’s first NMPA-approved quantitative diagnostic assay based on microRNA biomarkers.
-
Our best R&D capability is not to create a fancy idea. It is to take a doctor’s idea and bring it to life as a dependable IVD product.
Since its launch, the miRNA7 kit has been used in more than three million tests across China. It has improved early detection rates for high-risk populations, providing patients with earlier diagnoses and better treatment opportunities. It has become a trusted tool for clinicians that delivers reliable and actionable results. And for healthcare systems, it represents a scalable, efficient, and proven solution that adds value.
Building Long-Term Partnerships
The success of the miRNA7 kit highlights Dunwill’s focus on long-term partnerships with clients and collaborators. The company positions itself as a partner in innovation, working with hospitals, clinicians, and research institutions from the earliest stages of biomarker identification to the final step of product registration and adoption.
Clients appreciate this approach because it gives them a sense of ownership in the innovation process. When clinicians contribute to biomarker discovery, participate in validation, and provide ongoing feedback, they do not just use a diagnostic product—they help shape it. This sense of shared responsibility strengthens trust and ensures that the products developed are well-integrated into clinical practice.
Another reason Dunwill has earned a reputation for reliability is its flexibility. The company offers a broad range of IVD product platforms, enabling hospitals and research partners to choose the technologies that best align with their clinical needs. This adaptability ensures that products are scientifically rigorous and practically suited to diverse healthcare contexts.
Finally, Dunwill’s efficiency in product transformation and regulatory approval has proven invaluable. Navigating the regulatory landscape can be daunting, but Dunwill’s experience in NMPA registration and quality management enables smoother, faster, and more predictable pathways from discovery to commercialization. The result is an end-to-end, one-stop experience that reduces risks and accelerates time to market.
Quality without Compromise
Behind every successful diagnostic product lies a rigorous quality system. Dunwill operates with the understanding that quality and compliance are not optional add-ons, but the foundation of trust. The company’s manufacturing processes are ISO 13485-certified, its GMP facilities meet international standards, and its central laboratory aligns with CAP practices.
This emphasis on quality is not seen as a constraint on innovation but rather as an enabler. By maintaining frequent and open communication with regulatory authorities, Dunwill ensures that innovation proceeds in an orderly, reliable, and safe manner.
Physicians and patients alike can have confidence that every product has been tested, validated, and manufactured to the highest standards of precision and reproducibility.
Shaping the Future of Precision Medicine
Dunwill’s work does not stop with today’s diagnostics. The company is deeply committed to the future of precision medicine, continually investing in emerging technologies that will define the next generation of healthcare. Multi-omics platforms, single-cell and spatial biology, and AI-powered data mining are all areas of active development within Dunwill’s research framework.
By combining these advanced tools with its established model of clinician collaboration, the company ensures that its pipeline of biomarkers remains both cutting-edge and clinically relevant. Moreover, Dunwill pays particular attention to real-world data collection and investigator-initiated trials, allowing it to refine products after launch and continuously expand their clinical value. The iterative process ensures that diagnostics do not stagnate, but evolve alongside the needs of patients and healthcare providers.
As the field of precision medicine continues to evolve, Dunwill is committed to innovating responsibly, collaborating deeply, and ensuring that every step forward in science becomes a step forward for patients.
